Vandria

Vandria is a mitochondrial therapeutics company developing first-in-class small molecule mitophagy inducers to treat age-related and chronic diseases. Their lead program, VNA-318, targets early-stage CNS and neurodegenerative disorders to improve cognition and limit memory loss. Vandria also has a pipeline of other mitophagy-inducing molecules for muscle, lung, and liver diseases.

Buy Funded Startups lists

Funding Round: Series A

Funding Amount: $30.7M

Date: 21-Aug-2024

Investors: Hevolution Foundation, Dolby Family Ventures, ND Capital

Markets: Biotechnology, Therapeutics, Healthtech, Pharmaceutical

HQ: Lausanne, Vaud, Switzerland

Founded: 2021

Website: https://www.vandria.com/

LinkedIn: https://www.linkedin.com/company/vandria-sa

Twitter:

Instagram: